Orforglipron

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

Two new drugs, Orforglipron and Retatrutide, are set to redefine the obesity treatment landscape with their potential affordability and unprecedented efficacy, Scientific American reports. Potential Game Changers: Orforglipron, one of the two drugs, is anticipated to be easier to use, produce, and...